吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌临床观察  

Oxaliplatin combined with gemcitabine in the treatment of patients with advanced non-small cell lung cancer

作　　者：朱敬华[1] 江伟[1] 

机构地区：[1]江苏省肿瘤医院内科,南京210009

出　　处：《中国肺癌杂志》2007年第1期44-47,共4页Chinese Journal of Lung Cancer

摘　　要：背景与目的奥沙利铂在肺癌治疗中应用较少,本观察的目的为了解奥沙利铂联合吉西他滨治疗晚期非小细胞肺癌的疗效及毒副反应。方法对32例晚期非小细胞肺癌患者给予奥沙利铂65mg/m^2第1、8天静脉输注;吉西他滨800-1000mg/m^2,第1、8天静脉输注。21天为一个周期,完成2周期治疗后评价疗效。结果全组患者可评价疗效31例,无完全缓解,部分缓解7例,稳定15例,进展9例,总有效率22.6%,疾病控制率71.0%。中位疾病无进展生存7个月,中位生存期14.5个月。1年生存率59.0%,2年生存率45.8%。主要毒性反应为骨髓抑制和恶心呕吐。结论奥沙利铂联合吉西他滨治疗晚期非小细胞肺癌有一定疗效,可延长生存期,毒副反应可耐受,生存质量下降不明显。Background and objective The use of oxaliplatin is very little in the treatment of lung cancer. This study is designed to find out the efficacy and toxicity of the combination of oxaliplatin and gemcitabine in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods There were 32 cases of advanced NSCLC patients who were treated with oxaliplatin 65 mg/m^2 by intravenous infusion on the 1st and 8th days, and gemcitabine 800 -1000 mg/m^2 by intravenous infusion on the 1st and 8th days every 91 days. After 2 cycles the efficacy was evaluated. Results There were 31 cases that could be evaluated. No complete response was observed and the overall response rate was 22.6% （7 partial response）. The disease control rate was 71.0%. The median time to diease progression was 7 months and the median survival time was 14. 5 months. The 1 year survival rate was 59.0% and 2 year survival rate was 45.8%. The main toxicities were myelosuppression and nausea and vomiting. Conclusion The combination of oxaliplatin and gemeitabine is effective and well tolerated in the treatment of advanced NSCI,C. The quality of life is little influenced and the regimen also can prolong the survival time in some patients.

关 键 词：奥沙利铂 吉西他滨 晚期非小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]